Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $0.86 and traded as low as $0.8402. Brainstorm Cell Therapeutics shares last traded at $0.8514, with a volume of 24,158 shares changing hands.
Brainstorm Cell Therapeutics Price Performance
The stock has a 50-day simple moving average of $0.91 and a 200 day simple moving average of $0.86. The company has a market capitalization of $12.61 million, a PE ratio of -0.25 and a beta of 0.35.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last posted its earnings results on Monday, November 16th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, research analysts predict that Brainstorm Cell Therapeutics Inc. will post -3.01 EPS for the current fiscal year.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells. The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
